Evidence map›Paper›PMID 11036910›Full record

ReviewLancet (London, England)2000

The endotoxin-lipoprotein hypothesis.

M Rauchhaus, A J Coats, S D Anker

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Lancet (London, England), 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00795912 (A Study Of The Usage Of Statins In A Community Heart Failure Population), which is not on this map. Cited by 140 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 6 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00795912 phase4completedstarted 2003, after this paper: background citation

A Study Of The Usage Of Statins In A Community Heart Failure Population: The Impact of HMG Co-Enzyme A Reductase Inhibitors on Heart Structural Parameters, Brain Naturetic Peptide, Markers of Inflammation and Fibrosis

Ran2003Enrolled56Registered outcomes2Posted comparisons0ConditionsHeart FailureArmsAtorvastatin
PMID 11555537PMID 15302013PMID 12020481PMID 11996626PMID 15926863PMID 15313958PMID 14726474PMID 12034159PMID 12009719PMID 11806812PMID 11094035PMID 9922372other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 6 syntheses or guidelines pooled it, 530 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Impact of Preoperative Nutrition Status on Wound Healing in Patients With Chronic Limb-Threatening Ischemia Undergoing Endovascular Therapy.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Article
  18. The Obesity Paradox Revisited: Is Obesity Still a Protective Factor for Patients With High Comorbidity Burden or High-Complexity Procedures?Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2024
    Article
  19. Article
  20. Observational

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

M RauchhausDepartment of Clinical Cardiology, National Heart and Lung Institute, London, UK. m.rauchhaus@ic.ac.uk
A J Coats
S D Anker
Martin Luther University Halle-Wittenberg · DEMax Delbrück Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) has revolutionised the treatment of hypercholesterolaemia. Statin treatment, by lowering the atherogenic lipoprotein profile, reduces morbidity and mortality in patients with cardiovascular disease. Treatment with simvastatin causes a reduction of events of new-onset heart failure, but this may be attributable to properties other than its lipid-lowering effects. There is some evidence that lower serum cholesterol concentrations (as a surrogate for the totality of lipoproteins) relate to impaired survival in patients with chronic heart failure (CHF). Inflammation is a feature in patients with CHF and increased lipopolysaccharide may contribute substantially. We postulate that higher concentrations of total cholesterol are beneficial in these patients. This is potentially attributable to the property of lipoproteins to bind lipopolysaccharide, thereby preventing its detrimental effects. We hypothesise there is an optimum lipoprotein concentration below which lipid reduction would, on balance, be detrimental. We also propose that, in patients with CHF, a non-lipid-lowering statin (with ancillary properties such as immune modulatory and anti-inflammatory actions) could be as effective or even more beneficial than a lipid-lowering statin.

Indexed as

AnimalsAnticholesteremic AgentsCholesterolEndotoxinsHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaLipopolysaccharidesProtective AgentsProtein BindingSimvastatinAnticholesteremic AgentsCholesterolEndotoxinsHydroxymethylglutaryl-CoA Reductase InhibitorsLipopolysaccharidesProtective AgentsSimvastatin

Identifiers

PMID11036910
OpenAlexW2146902372

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.